European Commission logo
italiano italiano
CORDIS - Risultati della ricerca dell’UE
CORDIS

Wearable diagnostic for inflammation tracking for personalized patient care among at-risk patients

Descrizione del progetto

Un rilevatore indossabile per il monitoraggio delle informazioni biochimiche dei pazienti

Con la pandemia di Covid-19 che esaurisce le infrastrutture mediche in tutto il mondo, il settore della medicina personalizzata ha dovuto affrontare delle difficoltà. Uno dei maggiori ostacoli è stata l’assenza di monitoraggio in tempo reale dei parametri di salute nei pazienti. Ciò rende impossibile fornire tutti i vantaggi che altrimenti si potrebbero ottenere. Il progetto CytoTrack, finanziato dall’UE, risolverà questo problema introducendo un sistema indossabile che potrebbe tracciare in modo continuo e non invasivo le informazioni biochimiche e offrire importanti informazioni sulla salute in tempo reale. CytoTrack ha anche mostrato prospettive per l’uso nel monitoraggio dei pazienti a rischio per segni che potrebbero suggerire un’infezione da virus correlati all’influenza o altre condizioni e potrebbero salvarli da un’eventuale insufficienza d’organo potenzialmente letale.

Obiettivo

Xsensio is an innovation-driven Swiss company dedicated to solving one of the biggest challenges for
personalized medicine: the lack of real-time, continuous monitoring of health parameters in patients. Xsensio has built the highly modular CytoTrack breakthrough sensing platform to continuously and non-invasively track biochemical information as a wearable system and offer critical health insight in real time. CytoTrack has potential to continuously monitor inflammatory markers that tend to suddenly increase in at-risk patients, when infected by influenza-related viruses (e.g. COVID-19), or when undergoing powerful oncology treatments, exposing them to severe life-threatening organ failure. We have a passionate team of 7 PhDs, engineers and business people with expertise ranging from biochemistry and nanofluidics to data analytics and healthcare marketing, all committed to making the Lab-on-SkinTM a daily reality impacting tomorrow' s healthcare. In 2018, a 2-year agreement was signed with a top 10 biopharma company to leverage our cutting-edge solution for their oncology pipeline. Xsensio received many awards internationally, e.g. CES Innovation Award 2020 given to the world’s best innovations. Xsensio plans to grow a large, successful company, that becomes a European success story. While the preferred exit is an IPO, Xsensio remains open to other opportunities, including a trade sale. The milestones targeted in this proposal are critical to the future of Xsensio: they allow the company to build a strong platform of game-changing complementary diagnostic monitoring for the pharma industry to help predict the likely response and likely severe toxicity of their drugs during drug development and post-market surveillance. Investment from the EIC is critical to Xsensio as efforts to raise funds have proven to be challenging in the absence of preclinical data, putting the validation phase at risk of being delayed. Xsensio welcomes blended finance from the EC.

Invito a presentare proposte

H2020-EIC-SMEInst-2018-2020

Vedi altri progetti per questo bando

Bando secondario

H2020-EIC-SMEInst-2018-2020-3

Meccanismo di finanziamento

SME-2 - SME instrument phase 2

Coordinatore

XSENSIO SA
Contribution nette de l'UE
€ 1 756 693,75
Indirizzo
EPFL INNOVATION PARK, BUILDING C
1015 Lausanne
Svizzera

Mostra sulla mappa

PMI

L’organizzazione si è definita una PMI (piccola e media impresa) al momento della firma dell’accordo di sovvenzione.

Regione
Schweiz/Suisse/Svizzera Région lémanique Vaud
Tipo di attività
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Collegamenti
Costo totale
€ 2 509 562,50